Nothing Special   »   [go: up one dir, main page]

Dinday et al., 2015 - Google Patents

Large-Scale Phenotype-Based Antiepileptic Drug Screening in a Zebrafish Model of Dravet

Dinday et al., 2015

View PDF
Document ID
6213548258809151671
Author
Dinday M
Baraban S
Publication year

External Links

Snippet

Mutations in a voltage-gated sodium channel (SCN1A) result in Dravet Syndrome (DS), a catastrophic childhood epilepsy. Zebrafish with a mutation in scn1Lab recapitulate salient phenotypes associated with DS, including seizures, early fatality, and resistance to …
Continue reading at cyberleninka.org (PDF) (other versions)

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5082—Supracellular entities, e.g. tissue, organisms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic, hydroximic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca

Similar Documents

Publication Publication Date Title
Dinday et al. Large-scale phenotype-based antiepileptic drug screening in a zebrafish model of Dravet syndrome
Twig et al. The interplay between mitochondrial dynamics and mitophagy
Griffin et al. Preclinical animal models for Dravet syndrome: seizure phenotypes, comorbidities and drug screening
Ibhazehiebo et al. A novel metabolism-based phenotypic drug discovery platform in zebrafish uncovers HDACs 1 and 3 as a potential combined anti-seizure drug target
Nishimura et al. Using zebrafish in systems toxicology for developmental toxicity testing
JP6694026B2 (en) N-acetylmannosamine as a therapeutic agent
US11814681B2 (en) Method for predicting a subjects response to SLC modulator therapy
Shi et al. Developmental toxicity of cypermethrin in embryo-larval stages of zebrafish
Rockl et al. Skeletal muscle adaptation to exercise training: AMP-activated protein kinase mediates muscle fiber type shift
Kombian et al. Simultaneous LTP of non-NMDA-and LTD of NMDA-receptor-mediated responses in the nucleus accumbens
Li et al. The HMG-CoA reductase inhibitor lovastatin reverses the learning and attention deficits in a mouse model of neurofibromatosis type 1
O'Brien et al. Validating GSK3 as an in vivo target of lithium action
Fu et al. Metformin attenuates pressure overload-induced cardiac hypertrophy via AMPK activation
Sofi et al. Ceramide synthesis regulates T cell activity and GVHD development
US11041207B2 (en) Method for predicting a subject's response to valproic acid therapy
US20130023488A1 (en) Methods and compounds for reducing intracellular lipid storage
Federici et al. Paradoxical abatement of striatal dopaminergic transmission by cocaine and methylphenidate
Li et al. Implications of sphingolipids on aging and age-related diseases
Gupta et al. Importance of toxicity testing in drug discovery and research
US20210330611A1 (en) Therapy for neurological diseases/disorders
Xin et al. Hepatotoxicity of the pesticide avermectin exposure to freshwater-farmed carp: evidence from in vivo and in vitro research
Horváth et al. ATP-Evoked Intracellular Ca 2+ Signaling of Different Supporting Cells in the Hearing Mouse Hemicochlea
Dinday et al. Large-Scale Phenotype-Based Antiepileptic Drug Screening in a Zebrafish Model of Dravet
Fulks et al. Dopamine release and uptake impairments and behavioral alterations observed in mice that model fragile X mental retardation syndrome
Beech et al. Association of ion-channel genotype and macrocyclic lactone sensitivity traits in Haemonchus contortus